Plain-English translation of NCT04762199 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This study is testing whether a new medication called MRX-2843 works safely and effectively when combined with , a medication already used to treat advanced lung cancer. Both drugs are taken as daily pills. The trial will help doctors find the right dose of the new medication and understand how well the combination works against lung cancer that has spread.
Many patients with advanced lung cancer eventually stop responding to alone. This trial is exploring whether adding this medication to the existing treatment might help the cancer respond better and keep it under control longer.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will take both medications by mouth once daily in 28-day cycles, continuing as long as your cancer is stable and you are tolerating the treatment well. You will have regular clinic visits for blood tests, imaging scans, and check-ins with your doctor to monitor how you're responding and watch for any side effects. After you stop treatment, you'll be followed for at least 30 days to ensure any side effects have resolved.
AI-generated summary from trial data ยท Jun 30, 2026 ยท Not medical advice
United States